Tazemetostat
Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Explore 23 assets in Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05627245CT.gov Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tazemetostat (this asset) | National Cancer Institute (NCI) | P1 | CC · 43 |
| Adriamycin | Li Zhiming | P2/3 | BB |
| Prednisone | National Cancer Institute (NCI) | P2/3 | BB |
| Rituximab | Mayo Clinic | P2/3 | BB |
| Cyclophosphamide | Li Zhiming | P2/3 | BB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | BB |
| (+)-Vincristine | Li Zhiming | P2 | B |
| Azacitidine | National Cancer Institute (NCI) | P2/3 | B |
| Recombinant Human Hyaluronidase | National Cancer Institute (NCI) | P2/3 | B |
+15 more in the Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type cohort
Other indications for Tazemetostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P2 | BB · 70 |
| Epithelioid Sarcoma | — | P2 | BB · 70 |
| Kidney Medullary Carcinoma | — | P2 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tazemetostat in Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tazemetostat-diffuse-large-b-cell-lymphoma-germinal-center-b-cell-type
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →